605016.SS SHH
Shandong Bailong Chuangyuan Bio-Tech Co., Ltd.
1W: +3.2%
1M: -0.4%
3M: -18.1%
YTD: -15.3%
1Y: +4.3%
3Y: +50.9%
5Y: +112.2%
¥21.11 ($3.15)
+0.38 (+1.83%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$1.2B
+32.6% ▲
5Y CAGR: +22.3%
Gross Profit
$387M
+36.2% ▲
5Y CAGR: +19.5%
Operating Income
$285M
+27.5% ▲
5Y CAGR: +23.6%
Net Income
$246M
+27.3% ▲
5Y CAGR: +24.3%
EPS (Diluted)
$0.76
+26.7% ▲
5Y CAGR: +11.1%
EBITDA
$334M
+40.2% ▲
5Y CAGR: +21.8%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| Revenue | $500M | $653M | $722M | $868M | $1.2B |
| YoY Growth | +18.7% | +30.8% | +10.5% | +20.3% | +32.6% |
| Cost of Revenue | $336M | $472M | $493M | $584M | $765M |
| Gross Profit | $163M | $182M | $228M | $284M | $387M |
| Gross Margin | 32.7% | 27.8% | 31.7% | 32.7% | 33.6% |
| R&D Expenses | $15M | $23M | $27M | $33M | $44M |
| SG&A Expenses | $32M | $40M | $45M | $48M | $68M |
| Operating Expenses | $52M | $61M | $52M | $60M | $102M |
| Operating Income | $111M | $120M | $176M | $224M | $285M |
| Operating Margin | 22.2% | 18.4% | 24.4% | 25.8% | 24.8% |
| Interest Expense | $4M | $1M | $197K | $2M | $3M |
| Income Before Tax | $110M | $119M | $173M | $222M | $285M |
| Tax Expense | $15M | $14M | $22M | $29M | $40M |
| Net Income | $96M | $104M | $151M | $193M | $246M |
| Net Margin | 19.1% | 16.0% | 20.9% | 22.2% | 21.3% |
| EPS (Diluted) | $0.54 | $0.59 | $0.61 | $0.60 | $0.76 |
| EBITDA | $150M | $157M | $192M | $238M | $334M |
| Shares Outstanding | 178M | 178M | 248M | 322M | 323M |